// App-Quantinova.ai

2500 : A phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.

Researchers

Presenter

  • Jean-Charles Soria

Principal Investigators

  • Filippo G. De Braud

  • Ratislav Bahleda

  • Maria Gabriella Camboni

  • Renata Robert

  • Jeffrey D. Isaacson

  • Jason B. Litten

  • Andrew R. Allen

  • Lindsey Rolfe

  • Josep Tabernero

  • Barbara Adamo

  • Roberta Cereda

Medical Centers

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • DITEP, Drug Development Department, Institut Gustave Roussy, Villejuif, FranceGustave Roussy, Villejuif, FranceEOS S.p.A., Milan, Italy

  • Clovis Onc, San Francisco, CA

  • Clovis Oncology, Inc., Cambridge, United Kingdom

  • Institut de Recherches Internationales Servier, Suresnes, France

  • Clovis Oncology, Inc., Boulder, CO

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Locations

  • Italy

  • Spain

  • United Kingdom

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Lucitanib

Outcome

  • Positive

Study Design

  • pharmacokinetics

  • pharmacodynamics

Phase

  • NA

Study Id's

  • NCT01283945

Sponsors

  • Clovis Oncology

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved